EUCTR2010-019465-28-SE进行中（未招募）不适用
A randomised, double-blind, placebo-controlled, four-way crossover, repeat dose study comparing the effect of inhaled fluticasone furoate/GW642444M combination, GW642444M and fluticasone furoate on the allergen-induced asthmatic response in subjects with mild asthma.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Males and females aged 18 to 65 years inclusive.
- •2. Documented history of bronchial asthma, first diagnosed at least 6 months prior to the screening visit and currently being treated only with intermittent short-acting beta - agonist therapy by inhalation.
- •3. AST, ALT, alkaline phosphatase and bilirubin = 1.5xULN (isolated bilirubin
- •>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%)
- •4. Otherwise healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the GSK Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
- •5. Body mass index within the range 18.5-35.0 kilograms/metre2 (kg/m2).
- •6. A female subject is eligible to participate if she is of:
- •Non-childbearing potential defined as pre-menopausal females with a
- •documented tubal ligation or hysterectomy; or postmenopausal defined as 12
- •months of spontaneous amenorrhea [in questionable cases a blood sample with
- •simultaneous follicle stimulating hormone (FSH) > 40 MlU/ml and estradiol <
- •40 pg/ml (<140 pmol/L) is confirmatory]. Females on hormone replacement
- •therapy (HRT) and whose menopausal status is in doubt will be required to use
- •one of the contraception methods in Section 8.1 of the protocol, if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow
- •confirmation of post-menopausal status prior to study enrollment. For most
- •forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy
- •and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of
- •HRT during the study without use of a contraceptive method.
- •Child-bearing potential and agrees to use one of the contraception methods
- •listed in Section 8.1 for an appropriate period of time (as determined by the
- •product label or investigator) prior to the start of dosing to sufficiently minimize
- •the risk of pregnancy at that point. Female subjects must agree to use
- •contraception until 5 terminal half-live post-last dose.
- •7. Pre-bronchodilator FEV1 >70% of predicted at screening.
- •8. Subjects who are current non-smokers who have not used any tobacco products in the 6-month period preceding the screening visit and have a pack history of = 10 pack years. [number of pack years = (number of cigarettes per day/20) x number of years smoked]
- •9. Demonstration of a positive wheal and flare reaction (= 3 mm relative to negative
- •control) to at least one allergen from a battery of allergens (including house dust mite, grass pollen and cat hair) on skin prick testing at screening, or within 12 months of study start.
- •10. Methacholine challenge PC20< 8 mg/mL at screening.
- •11. Screening allergen challenge demonstrates that the subject experiences both an early and late asthmatic response. The early asthmatic response must include a fall in FEV1 of = 20% from the post saline value, on at least one occasion, between 5 and 30 minutes after the final concentration of allergen. The late asthmatic response must include a fall in FEV1 of = 15% from the post saline value, on at least three occasions, two of which mus
排除标准
- •1. Past or present disease, which as judged by the investigator or medical monitor, may affect the outcome of this study. These diseases include, but are not limited to,
- •cardiovascular disease, malignancy, gastrointestinal disease, hepatic disease, renal
- •disease, haematological disease, neurological disease, endocrine disease or
- •pulmonary disease (including but not confined to chronic bronchitis, emphysema,
- •bronchiectasis or pulmonary fibrosis).
- •2. Current or chronic history of liver disease, or known hepatic or biliary abnormalities
- •(with the exception of Gilbert's syndrome or asymptomatic gallstones)
- •3. Clinically significant abnormalities in safety laboratory analysis at screening.
- •4. Subject is hypertensive at screening. Hypertension at screening is defined as
- •persistent systolic BP >150 mmHg or diastolic BP > 90mmHg. Subject with controlled hypertension may be included.
- •5. Respiratory tract infection and/or exacerbation of asthma within 4 weeks prior to the first dose of study medication.
- •6. History of life-threatening asthma, defined as an asthma episode that required
- •intubation and/or was associated with hypercapnoea, respiratory arrest and/or hypoxic seizures.
- •7. Symptomatic with hay fever at screening or predicted to have symptomatic hayfever during days 14-22 of a treatment period of the study.
- •8. Administration of oral or injectable steroids within 5 weeks of screening or intranasal and/or inhaled steroids within 4 weeks of the screening visit.
- •9. Unable to abstain from other medications including non-steroidal anti-inflammatory
- •drugs (NSAIDs), anti-depressant drugs, anti-asthma anti-rhinitis or hay fever
- •medication, other than antihypertensive medication and paracetamol (up to 4 g per
- •day) for the treatment of minor ailments e.g. headache from 14 days before screening until the follow-up visit.
- •10. Unable to abstain from short acting beta agonists as described in the concomitant medications and non-drug therapies section.
- •11. Unable to abstain from antihistamines as described in the concomitant medications and non-drug therapies section.
- •12. If, after 2 concurrent administrations of saline during the allergen challenge at
- •screening the subjects still have a fall in FEV1 of greater than 10%.
- •13. The subject has participated in a study with a new molecular entity during the
- •previous 3 months or has participated in 4 or more clinical studies in the previous 12
- •months prior to the first dosing day.
- •14. History of milk protein allergy.
- •15. History of being unable to tolerate or complete allergen challenge tests.
- •16. Subject is undergoing allergen desensitisation therapy.
- •17. A known hypersensitivity to corticosteroids.
- •18. Any adverse reaction including immediate or delayed hypersensitivity to any
- •ß2-agonist or sympathomimetic drug, or known or suspected sensitivity to the
- •constituents of GW642444M inhalation powder (e.g., lactose, magnesium stearate).
- •19. There is a risk of non-compliance with study procedures.
- •20. History of blood donation (500 mL) within 3 months of starting the clinical study.
- •21. Subject is mentally or legally incapacitated.
- •22. Consumption of seville oranges, pummelos (members of the grapefruit family) or
- •grapefruit juice from 14 days prior to the first dose of study medication.
- •23. The subject regularly drinks more than 28 units of alcohol in a week if male, or 21
- •units per week if female. In general one unit of alcohol is defined as a medium (125
- •ml) glass of wine, half a pint (250 ml) of beer or one mea
研究者
相似试验
已完成
不适用
DSP-2230 Capsaicin and UVB Challenge StudyPeripheral Neuropathic PainSigns and SymptomsISRCTN80154838Sunovion Pharmaceuticals Europe Ltd56
进行中（未招募）
1 期
A randomised, double-blind, placebo-controlled, five parallel groups study investigating the efficacy and safety of BI 1356 BS (1mg, 5mg and 10mg administered orally once daily) over 12 weeks as add-on therapy in patients with type 2 diabetes and insufficient glycaemic control despite metformin therapy, including an open-label glimepiride treatment arm.Patients with type 2 diabetesMedDRA version: 8.1 Level: PT Classification code 10012613 Term: Diabetes mellitus non-insulin-dependentEUCTR2005-004597-24-GBBoehringer Ingelheim Limited375
进行中（未招募）
1 期
A randomised, double-blind, placebo-controlled, five parallel groups study investigating the efficacy and safety of BI 1356 BS (1mg, 5mg and 10mg administered orally once daily) over 12 weeks as add-on therapy in patients with type 2 diabetes and insufficient glycaemic control despite metformin therapy, including an open-label glimepiride treatment arm.Patients with type 2 diabetesMedDRA version: 8.1Level: PTClassification code 10012613EUCTR2005-004597-24-SEBoehringer Ingelheim AB500
进行中（未招募）
1 期
A randomised, double-blind, placebo-controlled, five parallel groups study investigating the efficacy and safety of BI 1356 BS (1mg, 5mg and 10mg administered orally once daily) over 12 weeks as add-on therapy in patients with type 2 diabetes and insufficient glycaemic control despite metformin therapy, including an open-label glimepiride treatment arm.Patients with type 2 diabetesMedDRA version: 8.1Level: PTClassification code 10012613EUCTR2005-004597-24-SKBoehringer Ingelheim Limited375
进行中（未招募）
不适用
A randomised, double-blind, placebo-controlled, five parallel groups efficacy and safety exploratory study comparing BI 1356 BS (1mg, 5mg and 10mg) to open label glimepiride each administered orally once daily over 12 weeks as add-on therapy in patients with type 2 diabetes and insufficient glycaemic control despite metformin therapyPatients with type 2 diabetesMedDRA version: 8.1Level: PTClassification code 10012613EUCTR2005-004597-24-DEBoehringer Ingelheim Pharma GmbH & Co. KG375